A phase I trial of AST-004, a novel combined adenosine A1R/A3R receptor agonist developed by Astrocyte pharmaceuticals, was reported. Preclinical studies have determined A3R expression is upregulated ...

Exploration of adenosine mechanism revealed adenosine receptors as a potentially useful target of therapy in RA.